Neos Therapeutics, Inc. (NASDAQ:NEOS) Q3 2019 Earnings Conference Call - Final Transcript
Nov 08, 2019 • 08:30 am ET
Thank you for holding. Good morning, and welcome to the Neos Therapeutics' Third Quarter 2019 Financial Results Conference Call. Today's call is being recorded. [Operator Instructions]
For introductory and opening remarks, I am turning the call over to Mr. Richard Eisenstadt, CFO of Neos Therapeutics. Please go ahead.
Thank you. Good morning, everyone, and welcome to our third quarter 2019 financial results conference call. This morning, we issued our financial results and corporate highlights press release, which is available on our website at www.neostx.com. I am joined on today's call by Jerry McLaughlin, our CEO.
Before we begin, I'd like to read the following regarding forward-looking statements. During this call, we will make statements related to our business that may be considered forward-looking and are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements concerning the commercialization of Adzenys XR-ODT, Cotempla XR-ODT and Adzenys ER oral suspension, the financial results of and outlook for our business including with respect to net revenue per pack, script volumes and market share, intended benefits of our commercial strategy, our expectations regarding the brand exclusivity for our ADHD products, our patient access program Neos Rx Connect, the capabilities of our technology and our research and development activities including the timing and progress of our product candidates, future expansion of our product pipeline to business development activities and our current and future financial position.
Forward-looking statements may often be identified with words such as we expect, we anticipate, upcoming or similar indications of future expectations. These statements reflect our views only as of today, and should not be reflected upon as representing our views as of any subsequent date. These statements are subject to a variety of risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the inherent risks associated with development and commercialization of our products and product candidates that we may not realize the intended benefits of our new commercialization strategy, and that preliminary or early indicators of performance may not reflect actual results of operations for any period. For a discussion on the material risks and other important factors that could affect our actual results, please refer to those contained in our most recent SEC filings.
I will now turn the call over to Jerry.
Thank you, Rich, and good morning, everyone. The team here at Neos has been executing on all fronts and I look forward to highlighting our accomplishments within our commercial business and our continued progress toward achieving profitability, as well as our advancing development pipeline and lead candidate NT0502, which we are developing for the treatment of chronic sialorrhea, commonly referred to as excessive drooling.
Specifically, for our ADHD business, we reported growth in net product sales and net revenue per pack for our core two products. Adzenys X-ODT and Cotempla XR-ODT. While overall prescription volumes dipped slightly this quarter, this is consistent with the change in commercial strategy we unveiled